CAFERGOT TABLET

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

CAFFEINE

Available from:

A. MENARINI SINGAPORE PTE. LTD.

ATC code:

N02CA52

Dosage:

100 mg

Pharmaceutical form:

TABLET

Administration route:

ORAL

Prescription type:

Prescription Only

Manufactured by:

NOVARTIS PHARMACEUTICALS UK LTD

Authorization date:

1988-05-12

Patient Information leaflet

CAFERGOT
®
antimigraine preparations.
COMPOSITION AND PHARMACEUTICAL FORM
Cafergot
®
  tablets  contain  1  mg  ergotamine  tartrate  and  100  mg 
caffeine.
For excipients, see section EXCIPIENTS.
INDICATIONS
Treatment of acute attacks of migraine.
DOSAGE AND ADMINISTRATION
Cafergot should be given at the first symptoms of an attack.
ADULTS
The first time Cafergot is taken, an initial dose of 2 Cafergot tablets 
orally is recommended. If relief is not obtained within half an hour, 
a further tablet should be administered; this may be repeated at 
half-hourly intervals, but the maximum daily dose indicated below 
should not be exceeded.
For  subsequent  attacks  the  initial  dose  may  be  increased  to  3 
tablets depending on the total dose required in previous attacks. 
If pain persists, additional doses of 1 tablet may be taken at half-
hourly intervals up to the maximum dose (see below).
THE FOLLOWING RESTRICTION MUST BE OBSERVED:
If  supplementary  antimigraine  medication  is  required,  the  use  of 
any  ergotamine-containing  preparations,  intranasal  or  parenteral 
dihydroergotamine or sumatriptan or other 5HT
1
-receptor agonists 
must be avoided (See section CONTRAINDICATIONS).
MAXIMUM DOSE PER ATTACK OR PER DAY
Adults: 6 mg ergotamine tartrate = 6 tablets.
MAXIMUM WEEKLY DOSE
Adults: 10 mg ergotamine tartrate = 10 tablets.
CONTRAINDICATIONS
Known  hypersensitivity  to  ergot  alkaloids,  caffeine,  or  any  other 
components of the formulations (see section EXCIPIENTS).
Pregnancy  and  breast-feeding  (see  section  PREGNANCY  AND 
LACTATION).
Peripheral  vascular  disorder,  impaired  peripheral  circulation, 
obliterative vascular disease, coronary heart disease, severe and/
or inadequately controlled hypertension, septic conditions, shock.
Severe renal or hepatic impairment.
Temporal arteritis.
Hemipleg